Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | MRD evaluation by MFC and NGS for MM

Francesca Gay • 7 Dec 2019
ASH 2019
Multiple Myeloma
FORTE

Speaking from the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL, Francesca Gay, MD, PhD, University of Turin, Turin, Italy, discusses the analysis and comparison of MRD data from the FORTE trial (NCT02203643) by multiparameter flow cytometry (MFC) and next generation sequencing (NGS). MRD assessment both by MFC and NGS showed a good concordance.

More from Francesca Gay

1:46
FORTE: MRD by MFC or NGS in myeloma
Francesca Gay • 14 Dec 2020
1:30
MRD: Paving the way for future clinical trials in myeloma
Francesca Gay • 14 Dec 2020
0:45
FORTE: KRd versus KCd treatment for myeloma
Francesca Gay • 14 Dec 2020
1:17
Predictors of early relapse in transplant-eligible MM patients
Francesca Gay • 7 Dec 2019

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals